Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07258095

INNOV5-MH-MAROC: Integrated Mental Health Care for Adolescents and Adults in Primary Care Centers and Schools in Morocco

Depression and anxiety are highly prevalent among adolescents and adults in Morocco, while access to evidence-based care in primary care centers and schools remains limited. This multicenter pragmatic randomized controlled trial evaluates an integrated mental health program inspired by WHO priorities. The INNOV5 intervention combines: (1) a collaborative care model in primary care; (2) mhGAP-based task-shifting and stepped care; (3) validated digital mental health interventions; (4) virtual reality exposure therapy for selected anxiety- or trauma-related cases; and (5) a school-based mental health promotion component in participating high schools. The primary objective is to compare the change in depressive symptoms (PHQ-9) at 6 months between INNOV5 and enhanced treatment as usual (TAU+). Secondary objectives include effects on anxiety (GAD-7), quality of life (WHOQOL-BREF), suicidal ideation and behavior (C-SSRS), functioning, school attendance, and feasibility and acceptability of the program.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Depression in Adolescence Anxiety Anxiety Disorders Behavior Behavioral Symptoms Depression Depression in Adults Mental Disorders Mental and Behavioural Disorders

Age range

12 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adolescents (12-17 years) and adults (≥18 years) attending participating primary care centres or high schools in Morocco.
  • Clinically significant depressive and/or anxiety symptoms identified by screening (PHQ-9 and/or GAD-7) according to study thresholds.
  • Able to understand study procedures and provide informed consent (or parental consent and adolescent assent for minors).
  • Planning to remain in the study area for at least 12 months.

Exclusion criteria

  • Acute psychiatric emergency requiring immediate specialised care (e.g. psychosis, high-risk suicidal crisis, severe substance use disorder).
  • Cognitive impairment or severe medical condition preventing participation in the intervention or assessments.
  • Current participation in another interventional mental health trial.
  • Any other situation judged by the investigator to make participation unsafe or inappropriate.

Treatment and study plan

INNOV5 Integrated Mental Health Program

Behavioral

Integrated multicomponent mental health program combining: (1) a collaborative care model in primary care; (2) mhGAP-based task-shifting and stepped care; (3) validated digital mental health interventions (apps and online tools); (4) virtual reality exposure therapy for selected anxiety- or trauma-related cases; and (5) a school-based mental health promotion component in participating high schools.

Enhanced Treatment as Usual (TAU+)

Behavioral

Usual mental health care and referrals available at participating primary care centers and schools, with minimal enhancements such as WHO mhGAP materials and basic information and referral resources, but without access to the INNOV5 integrated program components.

Primary outcomes

  1. Change in depressive symptoms (PHQ-9)

    Time frame: Baseline to 6 months

    Mean change in Patient Health Questionnaire-9 (PHQ-9) total score from baseline to 6 months comparing INNOV5 versus enhanced treatment as usual (TAU+). The PHQ-9 is a 9-item self-report scale of depressive symptoms; total scores range from 0 to 27, with higher scores indicating more severe depressive symptoms.

Secondary outcomes

  1. Change in anxiety symptoms (GAD-7)

    Time frame: Baseline to 6 months

    Mean change in Generalized Anxiety Disorder-7 (GAD-7) total score from baseline to 6 months between participants allocated to the INNOV5 integrated mental health program and those allocated to enhanced treatment as usual (TAU+). The GAD-7 is a 7-item self-report measure of anxiety symptoms; total scores range from 0 to 21, with higher scores indicating more severe anxiety.

Other outcomes

  1. Change in quality of life (WHOQOL-BREF)

    Time frame: Baseline to 6 months

    Change in health-related quality of life measured by the WHOQOL-BREF. The WHOQOL-BREF is a 26-item self-report questionnaire assessing four domains (physical health, psychological health, social relationships and environment). Domain scores are transformed to a 0-100 scale, with higher scores indicating better quality of life. Mean change in WHOQOL-BREF domain scores from baseline to 6 months will be compared between participants allocated to the INNOV5 integrated mental health program and those allocated to enhanced treatment as usual (TAU+).

Study contacts

Contact information is provided by the study sponsor or research team.

Younes MOUDAR, MPH

CONTACT

[email protected]

+41764429310

Sponsors and collaborators

Lead sponsor

Swiss Medical Academy Maroc

Other

Registry information

Official study title

INNOV5-MH-MAROC: Multicenter Pragmatic Randomized Controlled Trial Evaluating an Integrated Program of Five WHO Innovations in Mental Health in Morocco

Acronym: INNOV5-MH

Important dates

Study start
2028
Primary completion
2029
Study completion
2029
First posted
Dec 2, 2025
Registry last updated
Dec 2, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.